West Pharma beats Q4 earnings estimates, sets high 2026 guidance
West Pharmaceutical Services (NYSE:WST) shares gained momentum Thursday after the injectable-solution leader posted a fourth-quarter earnings beat and provided a bullish 2026 outlook, fueled by the explosive growth of GLP-1 "obesity" drugs and a massive jump in free cash flow.











